Archives of Clinical Rheumatology

Macrophage Activation Syndrome (MAS) is a severe inflammatory complication often linked to autoimmune disorders such as systemic lupus erythematosus (SLE). We describe a 57-year-old woman who presented with persistent fever, polyarthralgia, pancytopenia, and markedly elevated ferritin levels (>40,000 ng/mL). Extensive evaluation ruled out infection and malignancy. A diagnosis of MAS was made, and she responded well to high-dose corticosteroids and anakinra.

Acute gout flares cause severe pain, and conventional therapies are often contraindicated. Interleukin-1 (IL-1) inhibitors offer a targeted mechanism, but their efficacy and safety profile require systematic evaluation. This PRISMA-adherent systematic review and meta-analysis of 10 randomized controlled trials (n=1,731) assessed the efficacy and safety of IL-1 inhibitors (anakinra, canakinumab, rilonacept) versus active comparators or placebo.